NEW YORK - Eli Lilly and Co. said on Wednesday it is on track to launch its new depression drug this year following recent plant inspections by U.S. regulators, and that second-quarter earnings should hit the high end of its earlier estimates.... ...
Note: this page has been archived under Muzi Premium Version and is only available to premium members. Please use the Premium Personal Password (PPP) to log in.